BTIG Research Issues Positive Forecast for Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) had its target price hoisted by equities researchers at BTIG Research from $8.00 to $9.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. BTIG Research's target price suggests a potential upside of 40.41% from the stock's current price.

Separately, Piper Sandler boosted their price objective on Adaptive Biotechnologies from $6.00 to $7.00 and gave the stock an "overweight" rating in a report on Monday, November 11th.

Adaptive Biotechnologies Price Performance

Shares of ADPT traded down $0.11 during trading hours on Wednesday, hitting $6.41. The stock had a trading volume of 237,265 shares, compared to its average volume of 1,406,958. The firm has a 50 day simple moving average of $5.40 and a 200-day simple moving average of $4.61. The firm has a market capitalization of $945.98 million, a P/E ratio of -4.78 and a beta of 1.49. Adaptive Biotechnologies has a 1-year low of $2.28 and a 1-year high of $7.07.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ADPT. Millennium Management LLC increased its stake in shares of Adaptive Biotechnologies by 1,008.3% in the 2nd quarter. Millennium Management LLC now owns 9,262,341 shares of the company's stock worth $33,530,000 after acquiring an additional 8,426,580 shares during the last quarter. Rubric Capital Management LP increased its position in Adaptive Biotechnologies by 33.3% during the second quarter. Rubric Capital Management LP now owns 14,000,000 shares of the company's stock worth $50,680,000 after purchasing an additional 3,500,000 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in Adaptive Biotechnologies by 50.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 3,912,027 shares of the company's stock worth $14,162,000 after purchasing an additional 1,319,709 shares during the period. ARK Investment Management LLC raised its position in shares of Adaptive Biotechnologies by 8.1% during the 2nd quarter. ARK Investment Management LLC now owns 11,412,000 shares of the company's stock valued at $41,311,000 after buying an additional 850,704 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. grew its position in Adaptive Biotechnologies by 12.1% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 7,733,884 shares of the company's stock worth $39,597,000 after acquiring an additional 834,253 shares during the period. 99.17% of the stock is owned by hedge funds and other institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.